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Abstract
Background: Triangulation of data from multiple sources such as clinical cohort and surveillance data can help improve our
ability to describe care patterns, service utilization, comorbidities, and ultimately measure and monitor clinical outcomes among
persons living with HIV infection.
Objectives: The objective of this study was to determine whether linkage of clinical cohort data and routinely collected HIV
surveillance data would enhance the completeness and accuracy of each database and improve the understanding of care patterns
and clinical outcomes.
Methods: We linked data from the District of Columbia (DC) Cohort, a large HIV observational clinical cohort, with Washington,
DC, Department of Health (DOH) surveillance data between January 2011 and June 2015. We determined percent concordance
between select variables in the pre- and postlinked databases using kappa test statistics. We compared retention in care (RIC),
viral suppression (VS), sexually transmitted diseases (STDs), and non-HIV comorbid conditions (eg, hypertension) and compared
HIV clinic visit patterns determined using the prelinked database (DC Cohort) versus the postlinked database (DC Cohort + DOH)
using chi-square testing. Additionally, we compared sociodemographic characteristics, RIC, and VS among participants receiving
HIV care at ≥3 sites versus <3 sites using chi-square testing.
Results: Of the 6054 DC Cohort participants, 5521 (91.19%) were included in the postlinked database and enrolled at a single
DC Cohort site. The majority of the participants was male, black, and had men who have sex with men (MSM) as their HIV risk
factor. In the postlinked database, 619 STD diagnoses previously unknown to the DC Cohort were identified. Additionally, the
proportion of participants with RIC was higher compared with the prelinked database (59.83%, 2678/4476 vs 64.95%, 2907/4476;
P<.001) and the proportion with VS was lower (87.85%, 2277/2592 vs 85.15%, 2391/2808; P<.001). Almost a quarter of
participants (23.06%, 1279/5521) were identified as receiving HIV care at ≥2 sites (postlinked database). The participants using
≥3 care sites were more likely to achieve RIC (80.7%, 234/290 vs 62.61%, 2197/3509) but less likely to achieve VS (72.3%,
154/213 vs 89.51%, 1869/2088). The participants using ≥3 care sites were more likely to have unstable housing (15.1%, 64/424
vs 8.96%, 380/4242), public insurance (86.1%, 365/424 vs 57.57%, 2442/4242), comorbid conditions (eg, hypertension) (37.7%,
160/424 vs 22.98%, 975/4242), and have acquired immunodeficiency syndrome (77.8%, 330/424 vs 61.20%, 2596/4242) (all
P<.001).

http://publichealth.jmir.org/2018/1/e23/

XSL• FO
RenderX

JMIR Public Health Surveill 2018 | vol. 4 | iss. 1 | e23 | p.1
(page number not for citation purposes)

JMIR PUBLIC HEALTH AND SURVEILLANCE

Castel et al

Conclusions: Linking surveillance and clinical data resulted in the improved completeness of each database and a larger volume
of available data to evaluate HIV outcomes, allowing for refinement of HIV care continuum estimates. The postlinked database
also highlighted important differences between participants who sought HIV care at multiple clinical sites. Our findings suggest
that combined datasets can enhance evaluation of HIV-related outcomes across an entire metropolitan area. Future research will
evaluate how to best utilize this information to improve outcomes in addition to monitoring them.
(JMIR Public Health Surveill 2018;4(1):e23) doi:10.2196/publichealth.9221
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HIV/AIDS; health information technology; surveillance; retention; viral suppression; antiretroviral therapy

Introduction
A central feature of the updated 2020 National HIV/AIDS
(human immunodeficiency virus/acquired immunodeficiency
syndrome) Strategy is to measure progress along the HIV care
continuum to ensure that target goals are met for each stage.
The ability to monitor progress in meeting these goals is often
hampered by varying methodologies for data collection,
analyses, and variation in measurement approaches, with
estimates often relying on either clinic-level or population-based
data [1,2]. Both approaches have their advantages and
disadvantages. Clinic data provides more detailed and real-time
data from the site where care is being delivered, and whether
the patient kept or missed primary care visits. However,
compared with surveillance-based data, clinic data is less
informative for tracking patients who become incarcerated,
move, or transfer care [3-5]. These silent transfers of care and
the limitation that clinic-attending populations may not represent
the general population, present a challenge when trying to make
robust estimates of HIV care [6-8]. In contrast, surveillance data
are useful for monitoring population-based outcomes but
sometimes lack data accuracy and completeness for describing
patient-level characteristics and often are subject to reporting
time lags [9-16].
In the absence of a unified health record for HIV infected
persons, triangulating data from multiple sources such as clinical
cohort and surveillance data can help improve our ability to
describe care patterns, service utilization, comorbidities and
ultimately measure and monitor clinical outcomes. For example,
collaborations between local HIV clinics and health departments
seeking to identify out-of-care HIV infected patients have found
that their combined efforts resulted in timelier, more accurate
and complete data, and improved ascertainment of care status
[4,8,17,18].
The District of Columbia (DC) Cohort study is a prospective
observational clinical cohort study of persons living with
HIV/AIDS and receiving care across 13 clinical care sites in
Washington, DC [19]. Through an innovative data linkage
process,
DC
Cohort
participant
data,
including
sociodemographics, HIV-related diagnosis and laboratory
values, and sexually transmitted disease (STD) diagnosis data,
are matched with the DC Department of Health (DOH)
surveillance data every 6 months [19]. After recognizing the
limitations of each database alone, the linkage process was
designed to improve the completeness and accuracy of both
databases. The primary objectives of this analysis were to
perform an assessment of the utility of the linkage process in
http://publichealth.jmir.org/2018/1/e23/
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its ability to improve the completeness of the DC Cohort
database and the DOH data. We sought to do this by (1)
quantifying the differences between the pre-and postlinked
databases, (2) evaluating HIV care continuum outcomes, STD
diagnoses, and HIV clinic visit patterns using the prelinked
databases compared with the postlinked database, and (3) using
the postlinked database to compare sociodemographic
characteristics and HIV care continuum outcomes among
participants receiving HIV care at multiple sites.

Methods
Data Sources
The DC Cohort Study
Washington, DC has one of the highest HIV rates among cities
in the United States, with 2.0% of its population living with
HIV—about 14,000 residents as of 2015 [20]. The design of
the DC Cohort study, which began enrollment in 2011, has been
described previously [19,21,22]. Its source population consists
of adults and children diagnosed with HIV infection who
received outpatient HIV care at one or more DC Cohort sites
and consented to participate. Participants can consent to
participate at multiple clinics in which they receive HIV care.
DC Cohort sites include 8 hospital-based or affiliated sites and
5 community-based clinics that collectively serve over half of
persons living with HIV/AIDS (PLWHA) in DC [19,20].
Clinical data recorded during HIV care visits were abstracted
from each site’s electronic medical record and merged into a
centralized Web-based database (Discovere; Cerner Corporation,
Kansas City, MO) that collects data on demographics, diagnoses,
laboratory tests, pathology and clinical procedures, medications,
and drug resistance information. Informed consent included
participant acknowledgment of record linkage between patient
data collected by DC Cohort study sites and data reported to
DC DOH. The study protocol, consent forms, and research
instruments were approved by the George Washington
University Institutional Review Board (IRB), the DC DOH IRB,
and individual study sites’ IRBs [20].

DC Department of Health HIV/AIDS Hepatitis, STD,
Tuberculosis Administration
The DC DOH has conducted confidential name-based HIV
reporting since 2007 and HIV-related electronic laboratory data
reporting of cluster of differentiation 4 (CD4) counts and viral
load (VL) values since 2009 (22 District of Columbia Municipal
Regulations § 206, 21, 23). STD reporting is also conducted in
a confidential named-based manner, with over 45,000 syphilis,
JMIR Public Health Surveill 2018 | vol. 4 | iss. 1 | e23 | p.2
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gonorrhea, and chlamydia cases being reported annually [20].
The HIV/AIDS, Hepatitis, STD, Tuberculosis Administration
(HAHSTA) receives over 140,000 HIV- and STD-related
laboratory reports from 29 different laboratories annually
(HAHSTA internal communication).

Linkage of DC Cohort and DC Department of Health
HIV/AIDS Hepatitis, STD, Tuberculosis
Administration Data
Linkage Methods
Linkage of the DC Cohort and DC DOH databases is performed
semiannually and is ongoing. Data on DC Cohort patients
enrolled between January 1, 2011 and June 15, 2015 were linked
to this analysis. The linkage algorithm is shown in Figure 1.
First, each DC Cohort site sends a limited dataset electronically
via a secure file transfer protocol (FTP) site to the DC DOH.
The limited dataset includes the study ID, patient name, date of
birth, and social security number, if available. Simultaneously,
the DC Cohort Data and Statistics Coordinating Center (DSCC)
prepares a limited dataset for the DC DOH containing the study
identification (ID) as well as HIV-related variables collected at
the site. The DOH is authorized to receive both these files since
it is already authorized to receive named data on all persons
living with HIV/AIDS diagnosed with or receiving HIV care
in DC. Additionally, DC Cohort participants provided consent
for the linkage [9,23].
Data from the sites and the DSCC are then merged with data
from the DC enhanced HIV/AIDS Reporting System (eHARS)

Castel et al
and the STD surveillance database (STD*MIS). The postlinkage
database containing only the DC Cohort ID is sent back to the
DSCC through the FTP site.

Linkage Algorithm
Electronic linkage of HIV-related datasets is conducted using
an 11-key algorithm, using identifiers including patient first and
last name, date of birth, sex at birth and social security number.
For both the DC Cohort prelinked and DOH datasets, the
algorithm creates identifier-based keys that generated variables
to systematically match records in the datasets, while taking
into account the misspellings of names and data entry errors.
After these 11 variables are created in both datasets, each key
is matched separately, producing 11 discrete datasets that were
later merged and deduplicated by a patients’ study and eHARS
ID. Similarly, DC Cohort and STD surveillance data are matched
using a 10-key algorithm, based on identifiers such as first name,
last name, date of birth, and sex at birth. After linkage, the
combined dataset is deduplicated by study ID, disease type, and
disease date.

Postlinkage Database
Results from the match (the postlinked database) include data
on HIV, AIDS, and STD diagnoses, AIDS-defining opportunistic
infections (OIs), laboratory data such as CD4 counts and VL,
and vital status. Differences in laboratory dates or laboratory
values by the data source (DC Cohort vs DC DOH) are
reconciled using fuzzy matching. For the date of HIV or AIDS
diagnosis, the earlier date is used regardless of the data source.

Figure 1. Linkage algorithm for DC Cohort and DC Department of Health (DOH) data. DC DOH HAHSTA: DC Department of Health HIV/AIDS,
Hepatitis, STD, TB Administration; SSN: social security number; DOB: date of birth; PHI: personal health information; Surv.: surveillance; DSCC:
Data and Statistics Coordinating Center. Variables of interest include those variables that overlap between what is routinely collected in both the DC
Cohort and the DC DOH HAHSTA, including but not limited to dates of HIV diagnoses, CD4 (cluster of differentiation 4) and viral laboratory data,
opportunistic infections, and sexually transmitted disease diagnoses.
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The United States Centers for Disease Control and Prevention
surveillance guidelines regarding the hierarchical risk of HIV
transmission are used to reconcile differences in documented
transmission risk, independent of data source [24,25].

Eligibility Criteria
For this analysis, participants’ data were matched if they were
actively enrolled in the DC Cohort as of January 1, 2011, had
not withdrawn from the study, or transferred care to another
clinical site. To assess continuum of care measures such as
retention in care, we reviewed viral load, CD4 tests, and
encounters for those participants with at least 1 year of follow-up
for the period of June 15, 2014 to June 15, 2015. Participants
were considered lost-to-follow-up if, after manual review, no
laboratory data from either the DOH or the DC Cohort, and no
medical-chart based data from the DC Cohort data were
available for 18 months or longer as of June 15, 2015, as per
study protocol.

Receipt of Care by Number of Clinical Sites
To determine the number of clinical sites where a participant
was receiving care, CD4 and VL test results, proxies for HIV
care, were flagged as originating from either a DC Cohort site
or a non-DC Cohort site [26,27]. Receipt of care was grouped
into three categories: care at one, two, or three or more sites.
Care at one site included participants who only had labs from
their DC Cohort enrollment site. Care at two sites included
participants enrolled at only one DC Cohort site but who had
labs from another site (ie, either a non-DC Cohort site or a site
that was not their enrollment site). Care at three or more sites
included participants enrolled at only one DC Cohort who had
2 or more labs from two or more other sites (ie, either a non-DC
Cohort site or another DC Cohort site that was not their
enrollment site). Of note, additional labs obtained through the
linkage may have been related to HIV primary care or the result
of referrals to specialists who were also drawing HIV-related
labs. Since we were unable to determine the reason for the CD4
and VL tests conducted outside of the DC Cohort sites, receipt
of care at more than one site does not necessarily indicate receipt
of HIV primary care at more than one site.

HIV Care Continuum Outcomes: Retention in Care
on Antiretroviral Therapy and Viral Suppression
A participant was defined as meeting the definition of being
retained in care (RIC) if there was evidence of at least two
HIV-related encounters (eg, either HIV-related medical visit
and/or laboratory test results) at least 90 days apart in a
12-month period from June 15, 2014 to June 15, 2015
[6,16,28-31]. For the purposes of this analysis, a participant was
considered RIC even if the encounters occurred at multiple sites.
Being on antiretroviral therapy (ART) was defined as being
prescribed an ART regimen anytime during the study period,
that is, from June 15, 2014 to June 15, 2015. ART status was
based solely on prelinked data as ART data are not collected
by the DC DOH. Viral suppression (VS) was defined as
participants whose last VL on file was <200 copies/mL among
those who were retained in care and on ART.
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Statistical Analysis
Frequencies on demographic and clinical characteristics at study
enrollment (baseline) were computed in the prelinked DC Cohort
database, prelinked DC DOH database, and postlinked database.
Chi-square test statistics and Wilcoxon rank-sum tests were
used to determine differences among categorical and continuous
variables, respectively. Percent concordance between select
variables in the prelinked DC Cohort database and postlinked
databases were computed using kappa test statistics to assess
the comparative accuracy of the databases. Participant outcomes
(ie, RIC and VS) in the prelinked DC Cohort database and
postlinked database were compared. In the postlinked database,
participant demographic and clinical data were also compared
based on the number of sites where a participant had evidence
of receiving care (1 site, 2 sites, ≥3 sites). These comparisons
were made using chi-square test statistics. Statistical
comparisons with P values <.05 were considered statistically
significant. Analyses were conducted in SAS 9.3 (SAS Institute,
Inc., Cary, NC) and R (version 3.2.4).

Results
Assessment of Differences in Demographic and Clinical
Characteristics Between the Pre- and Postlinkage
Databases
The DC Cohort DSCC submitted data on 6054 study IDs to the
DC DOH of which 5633/5064 (93.05%) unique participants
matched to the DC DOH database and 421/6054 (6.95%) did
not (see Figure 2). Of those who did not match, 352/421 (83.6%)
were non-DC residents. Among those that matched, 5521/5633
(98.01%) were enrolled at a single DC Cohort site; 112/5521
(2.03%) were enrolled at more than one DC Cohort site. Of the
matched participants, 4476/5521 (81.07%) were actively
enrolled in the study with at least 1 year of follow-up by the
end of 2015.
The demographic and clinical characteristics are displayed by
the database from which they were calculated: the prelinked
DC Cohort database, the prelinked DC DOH database, and the
postlinked database as shown in Table 1. In the prelinked DC
Cohort database, among the 5521 participants enrolled at one
DC Cohort site, 25.99% (1435/5521) of the study sample was
female (data not shown), 4069/5521 (73.70%) non-Hispanic
black, and 4093/5521 (74.14%) were DC residents. Nearly 50%
(2220/4477) were identified as men who have sex with men
(MSM) as their HIV transmission risk. Mean age was 44 years
(data not shown) and mean time since HIV diagnosis was 14
years. Since enrollment, 4719/5333 (88.49%) participants had
ever been virally suppressed, 521/2273 (22.92%) had an OI at
AIDS diagnosis, and 2123/5521 (38.45%) had ever had an STD
diagnosis.
When comparing the prelinked DC Cohort database with the
postlinked database, a significantly higher percentage of
participants were found to be black, deceased, infected through
MSM sexual contact, to have had an OI at AIDS diagnosis, and
to have ever been virally suppressed. (P<.001 for all). The mean
duration of HIV diagnosis in the postlinked database increased
from 14 to 14.8 years, indicative of earlier diagnosis dates.
JMIR Public Health Surveill 2018 | vol. 4 | iss. 1 | e23 | p.4
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Additionally, the number of STD diagnoses increased from
2123 to 2739. Furthermore, post linkage, a higher percentage
of participants were Maryland and Virginia residents, more
infections were attributed to MSM sexual contact and fewer to
MSM/IDU, the mean duration of infection increased from 12.2
to 14.8 years, and the proportion of participants ever virally
suppressed increased (P<.001 for all).
Interrater reliability of selected variables that overlapped
between the prelinked DC Cohort database and the postlinked
database varied in agreement. There was strong agreement for
race/ethnicity (.75) and state of residence (.72); moderate
agreement for vital status (κ=.55) and OI at AIDS diagnosis
(κ=.40), and poor to fair agreement for transmission risk (κ=.36)
and whether a participant had ever been virally suppressed (ie,
<200 copies/mL; κ=.20).
The prelinked DC Cohort database included laboratory data
collected at clinical sites, while the prelinked DC DOH database
included laboratory data collected for surveillance purposes.
While the number of CD4 results were fairly similar when
comparing prelinked DC Cohort (n=33,505) and prelinked DC
DOH (n=35,990) databases, the number of VL results was not.
The prelinked DC Cohort database had 31,715 VL results, yet
the prelinked DC DOH database had only 12,381 VL results.

Castel et al

Differences in Demographic and Clinical
Characteristics by Number of HIV Care Sites
Differences in demographic and clinical characteristics of DC
Cohort participants who were matched through June 15, 2015
were assessed based on the number of HIV care sites using the
postlinked database. The number of sites where a participant
received HIV care was determined using the source of HIV labs.
Of the sample, 4242/5521 (76.83%) had evidence of receiving
HIV care at only one DC Cohort site, 855/5521 (15.49%) at
two sites, and 424/5521 (7.68%) at three or more sites (Table
2). Those who received care at three or more sites differed
demographically and clinically from those who received care
at fewer sites; they were more likely to be non-Hispanic black,
have a history of AIDS, be homeless or report temporary
housing, and to have been referred to substance use treatment.
Those receiving care at three or more sites were also more likely
to have public insurance, be enrolled in primary care at their
DC Cohort site, and receive care at a community-based DC
Cohort site. This group also fared worse clinically; they were
more likely to have lower CD4 counts (≤350 cells/mm3), have
a detectable VL (ie, >200 copies/mL), and have uncontrolled
viremia (ie, VL ≥100,000 copies/mL) on their most recent VL
test. They were also more likely to suffer from comorbid
conditions, including hypertension, cardiovascular disease, and
mental health issues (P<.001; Table 2) and more likely to have
died by June 2015.

Figure 2. Results of linkage of DC Cohort and DC Department of Health (DOH) surveillance data as of June 2015 (N=5521). DOH: Department of
Health; VL: viral load; CD4: cluster of differentiation 4.
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Table 1. Demographic and clinical characteristics of matched participants by data source (DC Cohort and DC Department of Health [DOH]) and linkage
status as of June 2015 (N=5521).
Characteristica

Prelinked DC

Prelinked

Postlinked

Prelinked DC

Prelinked

Agreement/concordance

cohort data,

DOHb data,

data, n (%)

cohort versus

DOH

between prelinked DC

postlinked

versus

cohort and postlinked

postlinked

data (Kappa)

n (%)

n (%)

c

(P value )

(P value)
Race/ethnicity
<.001

Non-Hispanic black

4069 (73.70)

4142 (75.02)

4175 (75.62)

.01

Non-Hispanic white

865 (15.67)

860 (15.58)

912 (16.52)

Other/unknownd

587 (10.63)

519 (9.40)

434 (7.86)

District of Columbia

4093 (74.14)

4088 (74.04)

4091 (74.10)

Maryland

1040 (18.84)

882 (15.98)

1042 (18.87)

Virginia

314 (5.69)

269 (4.87)

313 (5.65)

Other

74 (1.43)

282 (5.11)

75 (1.36)

106 (1.92)

122 (2.21)

163 (2.95)

<.001

.016

MSMf/IDUg

75 (1.68)

206 (4.31)

93 (1.74)

<.001

<.001

MSM

2220 (49.59)

2311 (48.36)

2850 (53.23)

Heterosexual

1519 (33.93)

1374 (28.75)

1439 (26.88)

Perinatal

223 (4.98)

.75

State of residence

Vital status

>.99

<.001
.72

.55

Transmission riske

Other

440 (9.83)

.36

215 (4.02)
888 (18.58)

757 (14.14)

Mean HIV duration in years (IQR ) 14.0 (8.3)

12.2 (7.0)

14.8 (8.2)

<.001

<.001

-

OIi at AIDS diagnosisj

521 (22.92)

975 (30.20)

981 (28.58)

<.001

.16

.40

Ever STDk

2123 (38.45)

694 (12.57

2739 (49.61)

-

-

-

Number of Viral Load labs

31,715

12,381

37,663

-

-

-

Number of CD4l labs

33,505

35,990

43,757

-

-

-

4719 (88.47)

2532 (47.48)

4848 (90.91)

<.001

<.001

.20

h

m

Ever virally suppressed
a

Date of birth and sex at birth were treated as matching variables for the linkage.

b

DOH: Department of Health.

c

P values for categorical variables were calculated using chi-square tests; P values for continuous distributions were obtained from Wilcoxon rank-sum
tests. P values in italics denote statistical significance at the .001 level.
d

Other race groups include those of multiple race group and unknown.

e

The denominator for transmission risk was 4477, 4779, and 5354 for prelinked DC Cohort data, prelinked DOH data and the postlinked data, respectively.

f

MSM: men who have sex with men.

g

IDU: male or female injection drug user.

h

IQR: interquartile range.

i

OI: opportunistic infection.

j

Opportunistic infections at AIDS diagnosis is an AIDS-defining condition that does not include those with CD4 counts <200 cells/mm3 or CD4% <14.
The denominator for OIs was 2273, 3229, and 3433 for prelinked DC Cohort data, prelinked DOH data, and postlinked data, respectively.
k

STD: sexually transmitted disease.

l

CD4: cluster of differentiation 4.

m

The denominator for ever virally suppressed was 5521, 5333, and 5333 for prelinked DC Cohort data, prelinked DOH data, and postlinked data,
respectively. Any viral load <200 copies/mL since enrollment was considered suppressed among participants enrolled anytime between January 1, 2011
and June 15, 2015.
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Table 2. Demographic and clinical characteristics of DC Cohort participants by number of sites where they were receiving HIV-related care (N=5521).
Characteristic

Totala

Care at 1 site

Care at 2 sites

Care at ≥3 sites

P valueb

Participants, n (%)

5521 (100.00)

4242 (76.8)

855 (15.49)

424 (7.68)

Not applicable

Mean age at entry (SD)

44.3 (13.2)

44.4 (13.4)

44.1 (912.9)

44.6 (11.4)

.63

1435 (25.99)

1011 (23.83)

280 (32.7)

144 (34.0)

Gender at birth, n (%)
Female

<.001

Race/ethnicity, n (%)
Non-Hispanic black

4175 (75.62)

3060 (72.14)

726 (84.9)

389 (91.7)

Non-Hispanic white

912 (16.52)

805 (18.98)

82 (9.6)

25 (5.9)

Other/unknownc

434 (7.86)

377 (8.89)

47 (5.5)

10 (2.4)
<.001

State of residence, n (%)
District of Columbia

4091 (74.09)

2915 (68.72)

770 (90.1)

406 (95.8)

Maryland

1042 (18.87)

958 (22.58)

69 (8.1)

15 (3.5)

Virginia

313 (5.67)

300 (7.07)

13 (1.5)

0 (0)

Other

75 (1.36)

69 (1.63)

3 (0.4)

3 (0.7)

163 (2.95)

110 (2.59)

31 (3.6)

22 (5.2)

Vital status (died), n (%)
Transmission riskd , n (%)

.001
<.001

MSMe/IDUf

93 (1.74)

58 (1.42)

20 (2.4)

15 (3.6)

MSM

2850 (53.23)

2293 (55.95)

386 (46.1)

171 (40.8)

Heterosexual

1439 (26.88)

1089 (26.57)

243 (29.0)

107 (25.5)

Perinatal

215 (4.02)

170 (4.15)

36 (4.3)

9 (2.1)

Other/unknowng

757 (14.14)

488 (11.91)

152 (18.2)

117 (27.9)
<.001

Housing status, n (%)
Permanent

4421 (80.07)

3445 (81.21)

663 (77.5)

313 (73.8)

Temporary

484 (8.77)

333 (7.85)

96 (11.2)

55 (13.0)

Homeless

66 (1.19)

47 (1.11)

10 (1.2)

9 (2.1)

Other/unknown

550 (9.96)

417 (9.83)

86 (10.1)

47 (11.1)
<.001

Employment status, n (%)
Working, full-time

1498 (27.13)

1320 (31.12)

150 (17.5)

28 (6.6)

Working, part-time

185 (3.35)

145 (3.42)

28 (3.3)

12 (2.8)

Unemployed

1373 (24.87)

940 (22.16)

270 (31.6)

163 (38.4)

Otherh

2465 (44.65)

1837 (43.31)

407 (47.6)

221 (52.1)
<.001

Insurance status, n (%)
Private

1697 (30.74)

1487 (35.05)

178 (20.8)

32 (7.5)

Public

422 (61.98)

2442 (57.57)

615 (71.9)

365 (86.1)

Other

402 (7.28)

313 (7.38)

62 (7.3)

27 (6.4)

Referral to drug treatment, n (%)

570 (10.32)

375 (8.84)

113 (13.2)

82 (19.3)

<.001

Ever AIDS, n (%)

3497 (63.34)

2596 (61.20)

571 (66.8)

330 (77.8)

<.001

Mean nadir CD4i cells/mm3 (SD)

330.7 (591.6)

329.2 (551.7)

335 (626.2)

336.9 (850.2)

.02

Most recent CD4 cells/mm, n (%)j
<50

51 (1.21)

25 (0.79)

10 (1.4)

16 (4.5)

50-200

282 (6.69)

170 (5.37)

65 (9.4)

47 (13.2)
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Totala

Care at 1 site

Care at 2 sites

Care at ≥3 sites

200-350

492 (11.67)

357 (11.27)

82 (11.8)

53 (14.9)

350-500

791 (18.76)

602 (19.00)

114 (16.5)

75 (21.1)

2601 (61.68)

2014 (63.57)

422 (60.9)

165 (46.3)

Characteristic

500+
Most recent viral load copies/ml, n (%)

k

P valueb

<.001

<200

3458 (83.83)

2729 (86.72)

518 (78.5)

211 (66.4)

200-1000

188 (4.56)

128 (4.07)

40 (6.1)

20 (6.3)

1000-10,000

183 (4.44)

120 (3.81)

39 (5.9)

24 (7.5)

10,000-50,000

182 (4.41)

104 (3.30)

40 (6.1)

38 (11.9)

50,000-100,000

66 (1.60)

39 (1.24)

14 (2.1)

13 (4.1)

100,000+

48 (1.16)

27 (0.86)

9 (1.4)

12 (3.8)

3790 (68.6)

2774 (65.39)

646 (75.6)

370 (87.3)

<.001

Mental health

2345 (42.47)

1650 (38.90)

435 (50.9)

260 (61.3)

<.001

Hypertension

1396 (25.29)

975 (22.98)

261 (30.5)

160 (37.7)

<.001

Cardiovascular

939 (17.01)

662 (15.61)

168 (19.6)

109 (25.7)

<.001

Hepatitis C

586 (10.61)

377 (8.89)

127 (14.9)

82 (19.3)

<.001

Diabetes

554 (10.03)

376 (8.86)

115 (13.5)

63 (14.9)

<.001

Respiratory

473 (8.57)

269 (6.34)

115 (13.5)

89 (21)

<.001

Chronic renal failure

462 (8.37)

310 (7.31)

94 (11.0)

58 (13.7)

<.001

Hepatitis B

136 (2.46)

107 (2.52)

7 (0.8)

22 (5.2)

.20

Chronic liver disease

139 (2.52)

106 (2.50)

20 (2.3)

13 (3.1)

.66

Primary care at DC Cohort site, n (%)
Comorbid conditions, n (%)

<.001

Type of clinic, n (%)
Hospital-based

3024 (54.77)

2563 (60.42)

365 (42.7)

96 (22.6)

Community-based

2497 (45.23)

1679 (39.58)

490 (57.3)

328 (77.4)

a

Data are for participants enrolled through June 15, 2015. Care at one site included singly-enrolled participants who had 0 or ≥1 lab from their DC
Cohort enrollment site. Care at two sites included singly-enrolled participants who had 0 or ≥1 lab from their DC Cohort enrollment site and ≥1 lab
from a second site (ie, a non-DC Cohort site or another DC Cohort site that was not their enrollment site). Care at three or more sites included singly-enrolled
participants who had 0 or ≥1 lab from their DC Cohort site and ≥2 labs from ≥2 other sites (ie, a non-DC Cohort site or another DC Cohort site that was
not their enrollment site).
b

P values for categorical variables were calculated using chi-square tests; P values for continuous distributions were obtained from Wilcoxon rank-sum
tests. P values in italics denote statistical significance at the .001 level.
c

Other race groups include those with multiple races and missing; unknown is unknown race/ethnicity.

d

The denominator for transmission risk was 5354, 4098, 837, and 419 for the total sample, care at 1 site, care at 2 sites, and care at ≥3 sites, respectively.

e

MSM: men who have sex with men.

f

IDU: male or female injection drug user.

g

Other transmission risk includes missing and risk not identified.

h

Other employment status includes student, disabled, retired and other/unknown.

i

CD4: cluster of differentiation 4.

j

The denominators for CD4 count are 4217, 3168, 693, and 356 for the total sample, care at 1 site, care at 2 sites, and care at ≥3 sites, respectively.

k

The denominators for viral load are 4125, 3147, 660, and 318 for the total sample, care at 1 site, care at 2 sites, and care at ≥3 sites, respectively.

http://publichealth.jmir.org/2018/1/e23/

XSL• FO
RenderX

JMIR Public Health Surveill 2018 | vol. 4 | iss. 1 | e23 | p.8
(page number not for citation purposes)

JMIR PUBLIC HEALTH AND SURVEILLANCE

Castel et al

Figure 3. Percentage of participants matched, retained in care, on antiretroviral therapy (ART) and having suppressed viral load (VL) in Washington,
DC 2014-2015 stratified by linkage status (pre vs post) (N=4476). The symbol "a" signifies DC Cohort participants who matched with DC Department
of Health records and were actively enrolled, not withdrawn, or transferred care from the Cohort, alive, and with at least 1 year of follow-up as of June
15, 2014. Retention in care was defined as matched participants with evidence of at least two HIV-related encounters (eg, either HIV-related medical
visit and/or laboratory test results) at least 90 days apart in a 12-month period from June 2014 to June 2015. Being on ART was defined as the number
of Cohort participants who were prescribed an antiretroviral therapy (ART) regimen that overlapped with the study period. ART status was based on
prelinked data as ART data are not collected by the DC DOH. Suppressed viral load (VL) was defined as matched participants whose last VL was <200
copies/mL among those who were retained in care and on ART.

Differences in Care Continuum Outcomes
Among the 4476 participants who were actively enrolled in the
study with at least 1 year of follow-up as of June 15, 2014, when
measuring the care continuum using the prelinked DC Cohort
database compared with the postlinked database, we found that
retention in care was higher (59.83% (2678/4476) vs 64.95%
(2907/4476); however, the proportion with viral suppression
was lower (87.85% (2277/2592) vs 85.15% (2391/2808) (P<.001
for both) (see Figure 3). The proportion of participants on ART
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was high at 96.79% (2592/2678), and was only able to be
assessed in the prelinked DC Cohort database. In the postlinked
database, the proportion of participants classified as retained
and as virally suppressed differed according to the number of
sites where care was being received (see Figure 4). Those
participants who received care at three or more sites were more
likely to meet the definition of retention in care (80.7%,
234/290) compared with those receiving care at one site
(62.61%, 2197/3509; P<.001) but were less likely to be virally
suppressed (72.3% (154/213) vs 89.51% (1869/2088); P<.001).
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Figure 4. Percentage of participants matched, retained in care, on antiretroviral therapy (ART) and having suppressed viral load (VL) in Washington,
DC 2014-2015 stratified by receipt of care at 1, 2 or ≥3 sites (N=4476). The letter "a" signifies DC Cohort participants who matched with DC Department
of Health records and were actively enrolled, not withdrawn or transferred care from the Cohort, alive, and with at least 1 year of follow-up as of June
15, 2014. Retention in care was defined as matched participants with evidence of at least two HIV-related encounters (eg, either HIV-related medical
visit and/or laboratory test results) at least 90 days apart in a 12-month period from June 2014 to June 2015. Being on ART was defined as the number
of Cohort participants who were prescribed an antiretroviral therapy (ART) regimen that overlapped with the study period. ART status was based on
prelinked data as ART data are not collected by the DC DOH. Suppressed viral load (VL) was defined as matched participants who had a VL test in
the time period and whose last VL was <200 copies/mL among those who were retained in care and on ART.

Discussion
Principal Findings
Linking clinical data collected in an observational HIV cohort
with routinely collected public health surveillance data was
mutually beneficial for both the clinical database as well as
public health surveillance efforts. Specifically, for the DC
Cohort, the linkage improved the accuracy of dates of diagnosis,
vital status, and modes of transmission and resulted in the
identification of more than 600 additional STD diagnoses, which
may otherwise have not been captured in the Cohort database.
From the DC DOH perspective, linkage of surveillance data to
the DC Cohort database found that the majority of participants
had been captured in the DC DOH surveillance data (93%)
consistent with the relatively high completeness of surveillance
reporting [32]. In addition, among those not matching, most
were not DC residents, highlighting the large volume of care
being delivered to non-DC residents by DC-based clinics. The
linkage also improved measurement of dates of diagnoses,
modes of transmission for HIV, and viral suppression for both
databases.
With respect to the completeness of laboratory reporting, the
linkage resulted in a substantial increase in the number of VLs
post linkage. Further examination of the VLs included in the
prelinked DC DOH surveillance data revealed that very few
results were under 200 copies/mL. This is also reflected in the
finding that only 47.5% of participants in the prelinked DC
DOH database had ever achieved viral suppression. Given that
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a relatively high proportion of individuals obtaining care in DC
have achieved an undetectable VL [33], this likely reflects that
although reportable, all VL values may not be as routinely
reported to the DC DOH surveillance program, whereas CD4
results are included in surveillance data regardless of the
numeric value [34]. Furthermore, because the prelinked DC
Cohort data includes non-DC residents using DC health care
facilities, VL labs for individuals who live outside of
Washington, DC, are reported to their respective health
departments and may not be captured in the DC DOH
surveillance database. Given the relatively high proportion of
non-DC residents participating in the Cohort who did not match
to the DC DOH surveillance database, this may further explain
the differences in VL reporting. The DC DOH surveillance
program is constantly striving to improve the completeness of
all laboratory reporting through routine checks with laboratory
facilities and standard regional data exchanges. Nevertheless,
despite the low initial number of VLs included in the DC DOH
database, they were still of added value to the DC Cohort
database.
Discriminating between DC Cohort and non-DC Cohort HIV
laboratories was also key to ascertaining whether participants
were coenrolled at more than one DC Cohort site or receiving
care at multiple sites throughout the city, or receiving care at
DC Cohort sites and non-DC Cohort sites. While most DC
Cohort participants were receiving care at one site, almost
one-quarter had evidence of receipt of HIV-related care at two
or more sites. Furthermore, participants with evidence of care
at three or more sites fared worse clinically and while they were
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most likely to be retained in care, they were less likely to be
virally suppressed. These findings were consistent with previous
analyses on-site migration in DC which also found lower CD4
and higher VLs among persons seeking care at more than one
site [35]. These trends may be reflective of other individual-level
factors such as homelessness, substance abuse, and more
fragmented care in general, among patients with multiple
comorbid conditions. Furthermore, this more vulnerable group
may have had seemingly higher retention in care as they may
have returned to care more often for follow-up visits based on
provider concerns about client health, fear of losing contact
with the most transient clients, or based on receipt of more
referrals to other clinics or specialists for their comorbid
conditions [35,36]. However, while a higher proportion of these
participants may have met the retention in care definition, their
care patterns appear to reflect more disparate care, as meeting
the definition did not translate into higher viral suppression.
Thus, given the complexity in measuring retention in care with
the shifting standards of clinical care and movement across
clinics, emphasis should be placed on achieving viral
suppression—a clear goal of treatment.
Additional laboratory data, used as supplemental and
complementary information, allowed for re-estimation of
retention and viral suppression and improved understanding of
drop-offs along the HIV care continuum. Using a nested care
continuum approach in which each step is dependent on the
prior step, our initial clinic-based care continuum would have
underestimated the percentage of participants meeting the
retention in care definition and overestimated viral suppression;
however, by combining additional laboratories from the health
department, we were able to achieve a more accurate measure
of these key indicators. Hence, routine data linkages such as
these could assist in refining the accuracy of care continua and
help prioritize clinical and public health interventions that seek
to re-engage persons who are not optimally in care [37,38].
Overall, our care continuum estimates were similar to those of
other HIV cohorts in the United States, including the HIV
Outpatient Study (HOPS), a convenience sample of patients at
selected HIV clinics in the United States, and the Medical
Monitoring Project (MMP) study, a multisite supplemental
surveillance system in the United States designed to provide
nationally representative data on PLWHA [38]. DC Cohort
estimates for proportion ‘on ART’ and viral suppression fell
within the range of HOPS and MMP estimates in 2012 (97%
and 92% on ART, respectively and 85% and 78% virally
suppressed, respectively). DC Cohort estimates were also
comparable to findings from the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD). Among
more than 35,000 NA-ACCORD participants with at least one
HIV care visit in the first 6 months of 2008, 82% were
prescribed ART and 78% had suppressed VLs [39].
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Limitations
This study has certain noteworthy limitations. Without knowing
the full context in which CD4 and VL labs were drawn, deriving
inference about the ability of DC Cohort participants to establish
and maintain a primary medical home for HIV care is a
challenge. We cannot exclude the possibility that additional labs
may be the result of referrals to specialists who are also drawing
HIV-related labs or acute encounters with the medical system
such as emergency department visits and hospitalizations. Given
the way laboratory results are reported, we are unable to fully
describe the source of the laboratory (eg, inpatient, emergency
department, outpatient, a specialty of reporting provider, etc),
which would allow for better characterization of care pattern
by type of encounter. However, additional analyses to determine
whether participants were receiving care sequentially at these
sites versus in an overlapping manner, may help further delineate
these care patterns. Finally, DC Cohort participants may not be
generalizable to all HIV-infected persons in DC, given that a
certain proportion of PLWH in DC is not consistently engaged
in care [30]. In future analyses, we intend to compare
characteristics of DC Cohort participants to city-wide HIV
population characteristics to assess whether Cohort-based care
estimates approximate care trajectories for the city as a whole.

Conclusions
Despite these limitations, this analysis represents a successful
triangulation of data from clinical cohort and public health
surveillance data and demonstrated that the data linkages were
mutually beneficial. The linkage not only helped to improve
the accuracy and completeness of each database but also helped
to describe care patterns among PLWHA, and enhanced
measurement of clinical outcomes and the HIV care continuum
at a population-level. The results derived through combining
these databases will help inform HIV programmatic efforts and
strengthen the DC DOH surveillance system as they will not
only enhance the completeness of case data but contribute to
the measurement of a more complete care continuum. The DC
Cohort intends to use these data to inform the development of
interventions focused on case management and improved care
coordination across clinical sites and across jurisdictions. The
DC DOH will be retooling its approaches to ensure continuity
of care in DC and the surrounding metropolitan area in an
enhanced data-to-care intervention strategy. With a more
complete and relevant dataset, DC DOH will collaborate with
community providers and deploy its public health team to
address interruptions in care. DC DOH also has a data sharing
agreement and protocol with Maryland and Virginia to ensure
that the most complete data available can be used to inform
jurisdictional partners in their data-to-care activities.
Performance and findings from this type of linkage provide a
reference point for design and interpretation of data from similar
data linkages in North America and could potentially be used
at the regional and national level as we strive to improve care
outcomes [28,39,40].
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